

Standing Group of Experts on Lumpy Skin Disease in Europe


under the GF-TADs umbrella

Fifth meeting (SGE LSD5)
Budva, Montenegro, 19-20 October 2017

Report by Bulgaria

Dr. Damyan Iliev CVO, OIE Delegate

1. LSD epidemiology – evolution since the SG4



2. Control measures applied



- 2.1 Legislative framework
- CID 2008/2016 amended by CID 2017/1460; CID 2016/2016 and
- Programme for protective measures against TADs, approved by SANTE/VP/2017/10527/EXOTIC DISEASES/BG
- 2.2 Clinical examination within the implementation of Surveillance programmes for other diseases (BT, TBC...)
- 2.2 Movement control
- 2.3. Vaccination




Standing Group of Experts on LSD in Europe under the GF-TADs umbrella

2. Control measures applied

2.3 Vaccination - annual revaccination of the bovine population has been completed, including vaccination of new born and traded


bovines

* the vaccination of calves reaching the age for vaccination and new traded bovine will continue



Name of vaccine	Number of vaccine doses	Number of bovines
	distributed	vaccinated
Lumpyvax	209 500	
BovivaxLSD-N	708 400	663 169
Total	917 900	

Vaccination plan for 2018



Standing Group of Experts on LSD in Europe under the GF-TADs umbrella





• Standing Group of Experts on LSD in Europe under the GF-TADs umbrella